InvestorsHub Logo
Followers 4
Posts 479
Boards Moderated 0
Alias Born 01/03/2015

Re: To infinity and beyond! post# 242884

Thursday, 09/27/2018 7:39:57 AM

Thursday, September 27, 2018 7:39:57 AM

Post# of 403036
I am confused by company's communication a bit. I agree 10k states that, but even recent PR implies analyzing P results is near term..differentiating from further developments of pill form in other indications. To me I read into it thinking either they are about to raise more capital enough to pay P and process legal documents for potential partnering or get partner and first priority to analyze P. Also, to me, the question is how much $ is needed and what is best way to get it.

Per PR stated by Dr B:

“Our clinical assets are both highly promising and well-diversified,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis; to analyze the Prurisol Phase 2b data in Psoriasis; and, as additional funding becomes available, to commence work on new product formulations
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News